SAN FRANCISCO, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced corporate presentations at the 7th Annual OneMedForum SF 2014, Biotech Showcase 2014 and the Southern California Investment Forum in San Francisco during the week of January 13, 2014.
- President & CEO Gerald Commissiong will present at OneMedForum at 2:30 PM PST on Monday, January 13, 2014 at the Westin Market Street. The presentation will be web cast live and available for replay at www.onemedplace.com/forum/webcast.
- A Company representative will present at Biotech Showcase on Wednesday, January 15, 2014 at 4:00 PM PST at the Parc 55 Wyndham Hotel. This presentation may be viewed live and will by archived at http://www.media-server.com/m/p/i98tbt59.
- An investment dinner presentation hosted by the Southern California Investment Forum (SCIF) will take place on Wednesday, January 15, 2014 at Morton's Steakhouse.
Company management and key advisors are available during this week in San Francisco for one-on-one meetings. If interested in scheduling a meeting, please contact email@example.com.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfoling-related apoptosis. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
The OneMedForum has become one of the world's pre-eminent healthcare growth company conferences. It attracts over 1000 leading investors, entrepreneurs and executives who have the chance to meet management of promising investment opportunities. Its panels provide a means to meet thought leaders and to gain strategic insight into capitalizing on the rapidly changing financing environment for healthcare and life science companies.
About Biotech Showcase
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
The Southern California Investment Forum, is an expansion of the ongoing road-show and conference activities of WallStreet Research™, a thirty year old independent research firm, which has been running conferences, road shows and investor gatherings nationally for over twenty years. WSR is today ranked NUMBER ONE on the Google, Yahoo, and Bing Search Engines, and its Small Cap Conferences are also ranked NUMBER ONE on the search engines.
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.
CONTACT: Investor/Media Contacts Aimee Boutcher, Director of Investor Relations Amarantus Bioscience Holdings, Inc. 973 332-0121 firstname.lastname@example.org
Source:Amarantus BioScience Holdings, Inc.